跳至主要内容
临床试验/NCT01722669
NCT01722669已完成早期 1 期

Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Hypercoagulable States.

Beth Israel Deaconess Medical Center1 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
入组人数
38
试验地点
1
主要终点
AUC

研究概览

简要总结

The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies

详细描述

To compare the absorption and activity of quercetin or isoquercetin with or without ascorbic acid in healthy adults. Oral chews containing quercetin (500mg) or isoquercetin(500 mg total) with or without ascorbic acid will be given. Pharmacokinetic parameters (AUC, Cmax, Tmax, elimination half-life) will be determined over 24 hours (8 time points). Pharmacodynamic inhibition of protein disulfide isomerase activity will also be assessed.

In addition to healthy subjects, a cohort of 10 individuals with antiphospholipid antibodies will participate. These participants will receive isoquercetin 1000 mg and have pharmacodynamics studies performed at time 0 and 4 hours.

All study drugs will be provided by Quercegen Pharma.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Quercetin

Experimental

Single dose of quercetin with or without ascorbic acid

干预措施: isoquercetin or quercetin (Drug)

Isoquercetin

Active Comparator

Single dose of isoquercetin with or without ascorbic acid

干预措施: isoquercetin or quercetin (Drug)

结局指标

主要结局

AUC

时间窗: 24 hours

AUC 0-24 hours of measured plasma quercetin aglycone for Arms A1, B1, A2, B2, C Collected at timepoints: baseline and 1, 2, 4, 6, 8, and 24 hours after dose. PK and PDI samples were not measured for Arm D (anti-phospholipid antibody cohort)

次要结局

  • Reductase Activity of PDI Using Dieosin Glutathione Disulfide(2 hours. Not measured in D)
  • Platelet-induced Thrombin Generation (U/mL)(4 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeff Zwicker

Associate Professor, Harvard Medical School

Beth Israel Deaconess Medical Center

研究点 (1)

Loading locations...

相似试验